Several biomarkers, including PD-L1 expression in tumor cells and immune cells (6), tumor mutational burden (TMB) (7), and microsatellite instability (MSI) (8), have been extensively investigated and demonstrated to be able to predict the response and the prognosis of patients treated with ICIs. This evidence concerns the gene CD274 and neoplasm.